These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9077372

  • 1. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhäger JC.
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [Abstract] [Full Text] [Related]

  • 2. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhäger JC.
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R, Marasi G, Vanasia A, Zoppi A, Lusardi P, Preti P.
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
    [Abstract] [Full Text] [Related]

  • 4. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 5. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR.
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [Abstract] [Full Text] [Related]

  • 6. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
    Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF.
    Nephrol Dial Transplant; 1993 Jun; 8(7):637-41. PubMed ID: 8396749
    [Abstract] [Full Text] [Related]

  • 7. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D, Hamood H, Morad N, Naschitz J.
    Harefuah; 2000 Apr 16; 138(8):650-3, 710. PubMed ID: 10883206
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
    Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, Gumbiner B, Ezetimibe Study Group.
    Eur Heart J; 2005 May 16; 26(9):897-905. PubMed ID: 15781429
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
    Lukacsko P, Walters EJ, Cullen EI, Niecestro R, Friedhoff LT.
    Curr Med Res Opin; 2004 Jan 16; 20(1):13-8. PubMed ID: 14741066
    [Abstract] [Full Text] [Related]

  • 10. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 16; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 11. [Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].
    Strano A, Novo S, Notarbartolo A, Davì G, Abrignani MG, Alaimo G, Averna MR, Barbagallo CM, Marino G.
    Cardiologia; 1989 Dec 16; 34(12):1027-33. PubMed ID: 2634479
    [Abstract] [Full Text] [Related]

  • 12. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J.
    Am J Cardiol; 2005 Feb 15; 95(4):462-8. PubMed ID: 15695129
    [Abstract] [Full Text] [Related]

  • 14. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 15; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 15. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M, Volpe M, Massaad R, Davies MJ, Allen C.
    Int J Cardiol; 2005 Jul 10; 102(2):327-32. PubMed ID: 15982505
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
    Fiorini F, Patrone E, Castelluccio A.
    Clin Ter; 1994 Sep 10; 145(9):213-7. PubMed ID: 7813167
    [Abstract] [Full Text] [Related]

  • 18. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
    Davidoff P, Ruiz F, Varas MA, García de los Ríos M, Silva MA, González G, Tapia JC.
    Rev Med Chil; 1991 Oct 10; 119(10):1140-6. PubMed ID: 1845208
    [Abstract] [Full Text] [Related]

  • 19. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
    Zubaid M, Shakir DK, Bazargani N, Binbrek A, Gopal R, Al-Tamimi O, Bakir S.
    J Cardiovasc Med (Hagerstown); 2008 Jul 10; 9(7):688-93. PubMed ID: 18545068
    [Abstract] [Full Text] [Related]

  • 20. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.
    Diabetes Res Clin Pract; 2004 May 10; 64(2):137-51. PubMed ID: 15063607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.